Literature DB >> 24569777

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

T Stübig1, H Alchalby1, M Ditschkowski2, D Wolf3, G Wulf4, T Zabelina1, C Wolschke1, F Ayuk1, N Kröger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24569777     DOI： 10.1038/leu.2014.86

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

Authors:  Haefaa Alchalby; Dinah-Rohina Yunus; Tatjana Zabelina; Guido Kobbe; Ernst Holler; Martin Bornhäuser; Rainer Schwerdtfeger; Wolfgang Bethge; Hans Michael Kvasnicka; Guntram Büsche; Francis Ayuk; Ulrike Bacher; Axel R Zander; Nicolaus Kröger
Journal:  Br J Haematol       Date:  2012-01-27       Impact factor: 6.998

2.  Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.

Authors:  J Thiele; H M Kvasnicka; H Dietrich; G Stein; M Hann; A Kaminski; N Rathjen; K A Metz; D W Beelen; M Ditschkowski; A Zander; N Kroeger
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303

3.  Bilateral toxoplasmosis retinitis associated with ruxolitinib.

Authors:  Roger A Goldberg; Elias Reichel; Lauren J Oshry
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

4.  Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

Authors:  G Caocci; F Murgia; L Podda; A Solinas; S Atzeni; G La Nasa
Journal:  Leukemia       Date:  2013-08-09       Impact factor: 11.528

5.  Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Authors:  M Massa; V Rosti; R Campanelli; G Fois; G Barosi
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

6.  Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

7.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

8.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

9.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

10.  Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

Authors:  Stefan O Ciurea; Barry Sadegi; Andrew Wilbur; Victoria Alagiozian-Angelova; Sujata Gaitonde; Lisa C Dobogai; Luke P Akard; Ronald Hoffman; Damiano Rondelli
Journal:  Br J Haematol       Date:  2008-04       Impact factor: 6.998
View more
  36 in total

1.  Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.

Authors:  A Hanif; P N Hari; E Atallah; K-S B Carlson; M C Pasquini; L C Michaelis
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 2.  Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Authors:  Vikas Gupta; Jason Gotlib; Jerald P Radich; Nicolaus M Kröger; Damiano Rondelli; Srdan Verstovsek; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-27       Impact factor: 5.742

Review 3.  Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 4.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 5.  Efficacy of ruxolitinib for myelofibrosis.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2014-05-24       Impact factor: 3.889

Review 6.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

7.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Authors:  Mohamed Shanavas; Uday Popat; Laura C Michaelis; Veena Fauble; Donal McLornan; Rebecca Klisovic; John Mascarenhas; Roni Tamari; Murat O Arcasoy; James Davies; Usama Gergis; Oluchi C Ukaegbu; Rammurti T Kamble; John M Storring; Navneet S Majhail; Rizwan Romee; Srdan Verstovsek; Antonio Pagliuca; Sumithira Vasu; Brenda Ernst; Eshetu G Atenafu; Ahmad Hanif; Richard Champlin; Paremeswaran Hari; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-19       Impact factor: 5.742

Review 8.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

Review 9.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 10.  Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?

Authors:  Auro Viswabandya; Rebecca Devlin; Vikas Gupta
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.